Back to Journals » International Journal of Nanomedicine » Volume 6

Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays

Authors Yang XQ, Chen C, Peng CW, Hou JX, Liu SP, Qi CB, Gong YP, Zhu XB, Pang DW, Li Y

Published 11 October 2011 Volume 2011:6 Pages 2265—2273

DOI https://doi.org/10.2147/IJN.S24161

Review by Single-blind

Peer reviewer comments 2

Xue-Qin Yang1,2, Chuang Chen1, Chun-Wei Peng1, Jin-Xuan Hou1, Shao-Ping Liu1, Chu-Bo Qi3, Yi-Ping Gong4, Xiao-Bo Zhu5, Dai-Wen Pang6, Yan Li1
1Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory on Tumor Biological Behaviors and Hubei Cancer Clinical Study Center, Wuhan; 2Medical School of Jingchu University of Technology, Jingmen; 3Department of Pathology; 4Department of Breast Surgery, Hubei Cancer Hospital, Wuhan; 5Wuhan Jiayuan Quantum Dots Co Ltd and Wuhan Tumor Nanometer Diagnosis Engineering Research Center, Wuhan; 6Key Laboratory of Analytical Chemistry for Biology and Medicine, College of Chemistry and Molecular Sciences, and State Key Laboratory of Virology, Wuhan University, Wuhan, People's Republic of China

Background: The epidermal growth factor receptor (EGFR) is a promising therapeutic target in cancer, but its clinical value in breast cancer remains controversial. Our previous studies have found that quantitative analysis of biomarkers with quantum dot-based nanotechnology had better detection performance than conventional immunohistochemistry. The present study was undertaken to investigate the prognostic value of EGFR in breast cancer using quantum dot-based quantitative spectral analysis.
Methods: EGFR expression in 65 breast cancer specimens was detected by immunohistochemistry and quantum dot-immunohistochemistry, and comparisons were made between the two methods. EGFR expression in tissue microarrays of 240 breast cancer patients was then detected by quantum dot-immunohistochemistry and spectral analysis. The prognostic value of EGFR immunofluorescence area (EGFR area) for five-year recurrence-free survival was investigated.
Results: The same antigen localization, high correlation of staining rates (r = 0.914), and high agreement of measurement (κ= 0.848) of EGFR expression in breast cancer were found by quantum dot-immunohistochemistry and immunohistochemistry. The EGFR area showed significant differences by tumor grade, lymph node status, HER2 status, and hormone receptor status (all P < 0.05). Patients in the large EGFR area (≥30.51) group had a significantly higher five-year recurrence rate (47.2% versus 27.4%, P = 0.002) and worse five-year recurrence-free survival (log-rank test, P = 0.0015) than those in the small EGFR area (<30.51) group. In the subgroups, EGFR area was an independent prognosticator in the HER2-positive and lymph node-positive subgroups.
Conclusion: Quantum dot-based quantitative detection demonstrates the prognostic value of EGFR area in the HER2-positive and lymph node-positive subgroups of invasive breast cancer.

Keywords: quantum dots, breast cancer, epidermal growth factor receptor, quantitative analysis, recurrence-free survival, prognosis
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Quantum dot-based multiplexed imaging in malignant ascites: a new model for malignant ascites classification

Zeng WJ, Peng CW, Yuan JP, Cui R, Li Y

International Journal of Nanomedicine 2015, 10:1759-1768

Published Date: 5 March 2015

Readers of this article also read:

Corrigendum

Wu Q, Chu M

International Journal of Nanomedicine 2012, 7:4531-4532

Published Date: 15 August 2012

Erratum

Marusza W, Mlynarczyk G, Olszanski R, Netsvyetayeva I, Obrowski M, Iannitti T, Palmieri B

International Journal of Nanomedicine 2012, 7:4119-4120

Published Date: 27 July 2012

Corrigendum

Hong SH, Kim JE, Kim YK, Minai-Tehrani A, Shin JY, Kang B, Kim HJ, Cho CS, Chae C, Jiang HL, Cho MH

International Journal of Nanomedicine 2012, 7:3069-3070

Published Date: 20 June 2012

Translocation of PEGylated quantum dots across rat alveolar epithelial cell monolayers

Fazlollahi F, Sipos A, Kim YH, Hamm-Alvarez SF, Borok Z, Kim K-J, Crandall ED

International Journal of Nanomedicine 2011, 6:2849-2857

Published Date: 10 November 2011

Erratum

Iancu C, Mocan L

International Journal of Nanomedicine 2011, 6:2543-2544

Published Date: 21 October 2011

Biomimetic component coating on 3D scaffolds using high bioactivity of mesoporous bioactive ceramics

Yun HS, Kim SH, Khang DW, Choi JI, Kim HH, Kang MJ

International Journal of Nanomedicine 2011, 6:2521-2531

Published Date: 21 October 2011

Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsions

Tavares ER, Freitas FR, Diament JD, Maranhão RC

International Journal of Nanomedicine 2011, 6:2297-2304

Published Date: 12 October 2011

Multi-access drug delivery network and stability

Mitatha S, Moongfangklang N, Jalil MA, Suwanpayak N, Ali J, Yupapin PP

International Journal of Nanomedicine 2011, 6:1757-1764

Published Date: 23 August 2011